Showing results (161-170 of 419) with videos related to
Sort By:
Pageof 42
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.Current Oncology Reports|November 8, 2024
Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art ReviewVivek Podder, Shreyas Bellur, Kim Margolin, et al.Journal of Surgical Oncology|February 27, 2010
Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approachDavid Reynoso, Vivek Subbiah, Jonathan C Trent, et al.Cancer Letters|January 8, 2025
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor modelUjjwol Khatri, Mohamed A Gouda, Shriya Pandey, et al.Cancers|September 28, 2023
Dosimetry of a Novel 111Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human PrimatesGregory Ravizzini, William Erwin, Louis De Palatis, et al.Oncotarget|July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitorsIshwaria M Subbiah, Chad Tang, Arvind Rao, et al.Cold Spring Harbor Molecular Case Studies|August 27, 2020
Dual inhibition of BRAF and mTOR in BRAF -mutant pediatric, adolescent, and young adult brain tumorsShiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.Current Oncology (Toronto, Ont.)|June 26, 2024
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed StrategyMohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.JCO Clinical Cancer Informatics|January 18, 2019
High-Throughput Architecture for Discovering Combination Cancer TherapeuticsMatt Gianni, Yong Qin, Geert Wenes, et al.Journal of Hematology & Oncology|August 3, 2014
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trialVivek Subbiah, Funda Meric-Bernstam, Gordon B Mills, et al.Pageof 42